Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 9/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.73 |
| ▸ | DRD2 | P14416 | 2/20 | 0.73 |
| ▸ | DRD4 | P21917 | 2/20 | 0.73 |
| ▸ | DRD3 | P35462 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HTR1B | P28222 | 1/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12629128 | 0.87 | DRD2 (0.67) | HTR1ASLC6A4DRD2DRD4DRD3 | |
| SCHEMBL7206828 | 0.85 | DRD2 (1.00) | HTR1ASLC6A4DRD2DRD4DRD3 | |
| SCHEMBL12629127 | 0.83 | DRD2 (0.68) | HTR1ASLC6A4DRD2DRD4DRD3 | |
| SCHEMBL7297780 | 0.82 | ADRB3 (0.68) | HTR1ADRD4DRD3KMT2AHTR1B | |
| SCHEMBL7285328 | 0.81 | ADRB3 (0.67) | HTR1ADRD4DRD3KMT2AHTR1B | |
| SCHEMBL7296273 | 0.81 | ADRB3 (0.67) | HTR1ADRD4DRD3KMT2AHTR1B | |
| SCHEMBL7846504 | 0.81 | HTR1A (1.00) | HTR1ASLC6A4DRD2DRD4DRD3 | |
| SCHEMBL9096899 | 0.81 | HTR1A (0.65) | HTR1ASLC6A4DRD2DRD4DRD3 | |
| SCHEMBL10731550 | 0.80 | DRD2 (0.62) | HTR1ASLC6A4DRD2DRD4DRD3 | |
| SCHEMBL10736268 | 0.80 | DRD2 (0.62) | HTR1ASLC6A4DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0923548-B1 | 4-AMINOETHOXY INDOLES AS DOPAMIN D2 AGONISTS AND AS 5HT 1A LIGANDS | WYETH CORP (US) | 2003-03-12 | — | — | EP | claimed |
| US-5958965-A | TREATMENT OF DISEASES ATTENDING DISTURBANCES IN THE SEROTINERGIC SYSTEMS, SUCH AS ANXIETY, STRESS, DEPRESSION, SEXUAL DYSFUNCTIONS AND SLEEP DISTURBANCES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-09-28 | — | — | US | claimed |
| EP-0923548-A1 | 4-AMINOETHOXY INDOLES AS DOPAMIN D2 AGONISTS AND AS 5HT 1A? LIGANDS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-06-23 | — | — | EP | claimed |
| WO-1998008817-A1 | 4-AMINOETHOXY INDOLES AS DOPAMIN D2 AGONISTS AND AS 5HT1A LIGANDS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-03-05 | — | — | WO | claimed |
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-24 | — | — | US | disclosed |
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-24 | — | — | US | disclosed |
| EP-0923548-B1 | 4-AMINOETHOXY INDOLES AS DOPAMIN D2 AGONISTS AND AS 5HT 1A LIGANDS | WYETH CORP (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-0923551-B1 | 4-AMINOETHOXY INDOLONE DERIVATIVES | AMERICAN HOME PROD (US) | 2002-06-05 | — | — | EP | disclosed |
| US-5958965-A | TREATMENT OF DISEASES ATTENDING DISTURBANCES IN THE SEROTINERGIC SYSTEMS, SUCH AS ANXIETY, STRESS, DEPRESSION, SEXUAL DYSFUNCTIONS AND SLEEP DISTURBANCES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0923551-A1 | 4-AMINOETHOXY INDOLONE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-06-23 | — | — | EP | disclosed |
| EP-0923548-A1 | 4-AMINOETHOXY INDOLES AS DOPAMIN D2 AGONISTS AND AS 5HT 1A? LIGANDS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-06-23 | — | — | EP | disclosed |
| US-5817690-A | ANTIDOPAMINE AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-10-06 | — | — | US | disclosed |
| WO-1998008819-A1 | 4-AMINOETHOXY INDOLONE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-03-05 | — | — | WO | disclosed |
| WO-1998008817-A1 | 4-AMINOETHOXY INDOLES AS DOPAMIN D2 AGONISTS AND AS 5HT1A LIGANDS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | CHRM2, ADRB2, CHRM3 | HTR1A 429/4885SLC6A4 958/4885DRD2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.